Inclusion Criteria:  Maternal age greater than or equal to 18 Singleton or multifetal pregnancy Able to receive neuraxial analgesia Planned/ scheduled Cesarean delivery OR non-urgent Cesarean delivery at UnityPoint-Health Meriter with adequate time to consider and consent to the study Able to provide consent in English  Exclusion Criteria:  Known hypersensitivity to bupivacaine or liposomal bupivacaine (defined as a history of a reaction or allergy to bupivacaine (injectable, intravenous, or transdermal) reported by patient or documented in the medical record) or patient report Plan by the obstetrical provider to inject bupivacaine or other local anesthetic into the cesarean incision due to potential differences in pain levels. Contraindication to regional analgesia Positive urine drug screen at admission to the hospital, if ordered for clinical purposes. Current opioid use or opioid use disorder per patient report or documented in the medical record or the Enhanced Prescription Drug Monitoring Program (ePDMP) (reviewed by Principal Investigator 1-14 days prior to surgery) Chronic opioid use or opioid use disorder, either patient reported or documented in the medical record or the ePDMP (reviewed by PI 1-14 days prior to surgery), defined as opioid use on most days for greater than 3 months Planned Cesarean hysterectomy (excluded due to anticipated blood loss and alternative pain control measures, possible prolonged intubation) Planned vertical midline incision Presence of renal dysfunction precluding the use of non-steroidal anti-inflammatory drugs (NSAIDs) Ischemic heart disease, congestive heart failure, or cardiomyopathy of pregnancy Coagulopathy Planned discharge from the hospital less than 48 hours postpartum